CD79A and peeling skin syndrome: Although the rate of immunoglobulin replacement requirement in our pSS cohort is lower compared with up to 11% in other diseases such as AAV (46), immunoglobulin (IgM, IgA, and IgG) levels need to be monitored before and after rituximab therapy to make an informed decision about SIE risk during repeat cycles (44, 47).